QQ客服 官方微博 反馈留言

浏览/检索结果: 共3条，第1-3条 帮助 限定条件 专题：合肥物质科学研究院    第一署名单位    第一作者单位    通讯作者单位     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Crosstalk between the gut microbiome and clinical response in locally advanced thoracic esophageal squamous cell carcinoma during neoadjuvant camrelizumab and chemotherapy 期刊论文 ANNALS OF TRANSLATIONAL MEDICINE, 2022 作者:  Xu, Liwei;  Qi, Yajun;  Jiang, Youhua;  Ji, Yongling;  Zhao, Qiang 收藏  |  浏览/下载：30/0  |  提交时间：2022/05/05 Gut microbiome  esophageal squamous cell carcinoma (ESCC)  neoadjuvant therapy  immunotherapy   High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma 期刊论文 BMC CANCER, 2022, 卷号: 22 作者:  Chen, Xi;  Kong, Haiying;  Luo, Linxiang;  Han, Shuiyun;  Lei, Tao 收藏  |  浏览/下载：43/0  |  提交时间：2022/02/14 Hodgkin lymphoma  PD-1 inhibitor  PD-L1 inhibitor  PD-L2  Molecular phenotype  Tumor microenvironment   AdvanTIG-302: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus tislelizumab (TIS) versus pembrolizumab (PEM) in programmed death ligand-1 (PD-L1) selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC). 期刊论文 JOURNAL OF CLINICAL ONCOLOGY, 2021, 卷号: 39 作者:  Socinski, Mark A.;  Spira, Alexander I.;  Paz-Ares, Luis G.;  Reck, Martin;  Lu, Shun 收藏  |  浏览/下载：31/0  |  提交时间：2022/01/10